Literature DB >> 11181910

Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics.

M E Anderson1, A Mazur, T Yang, D M Roden.   

Abstract

Quinolones are clinically important antibiotic drugs. One quinolone antibiotic, sparfloxacin (SPX), has been recently reported to increase the QT interval, and another quinolone, grepafloxacin (GRX), was withdrawn because it induced torsade de pointes (TdP), a polymorphic ventricular tachycardia (VT) linked to excessive QT interval prolongation. To determine whether SPX, GRX, and other recently developed quinolones, gatifloxacin (GAT) and moxifloxacin (MOX), have similar, potentially deleterious, properties we compared these agents in two ways. First, we measured their relative antagonist potency against the rapid component of the delayed rectifier K(+) current (I(Kr)), and second we determined the QT interval prolongation and inducibility of VT and TdP using a well established in vivo rabbit arrhythmia model. All of these agents are I(Kr) antagonists with the following IC(50) values (mean +/- S.E.) for I(Kr) block: SPX, 0.23 +/- 0.07 microM; MOX, 0.75 +/- 0.31 microM; GAT, 26.5 +/- 13.4 microM; and GRX, 27.2 +/- 11.6 microM. All agents also increased the maximum QT interval (mean +/- S.E.) from baseline (241 +/- 10 ms): SPX, 370 +/- 30 ms; MOX, 270 +/- 30 ms; GRX, 280 +/- 25 ms; and GAT, 255 +/- 23 ms. No agents caused TdP during a standard 30-min observation period, but SPX-treated animals developed nonsustained VT (three of six) and TdP (one of six) during an extended 60-min observation period. These findings show that I(Kr) block may be a common feature of many quinolone antibiotics, and that the proarrhythmic consequences vary according to I(Kr) antagonist potency, but are also influenced by additional, unidentified factors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181910

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  27 in total

1.  Torsades de pointes induced by garenoxacin in association with pacing failure in an elderly woman with VDD pacemaker.

Authors:  Ryozo Yoshioka; Masao Sakabe; Hideshi Toyama; Yusuke Muro; Akira Fujiki
Journal:  J Cardiol Cases       Date:  2011-02-20

2.  Possible mechanisms of sudden cardiac death in top athletes: a basic cardiac electrophysiological point of view.

Authors:  András Varró; István Baczkó
Journal:  Pflugers Arch       Date:  2010-02-26       Impact factor: 3.657

Review 3.  Safety considerations of fluoroquinolones in the elderly: an update.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

Review 4.  Safety profile of the fluoroquinolones: focus on levofloxacin.

Authors:  Hans H Liu
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

Review 5.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Fluoroquinolones in the elderly: safety considerations.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin.

Authors:  Nikunjkumar Patel; Oliver Hatley; Alexander Berg; Klaus Romero; Barbara Wisniowska; Debra Hanna; David Hermann; Sebastian Polak
Journal:  AAPS J       Date:  2018-03-14       Impact factor: 4.009

8.  Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance.

Authors:  Luigi X Cubeddu
Journal:  Curr Cardiol Rev       Date:  2009-08

Review 9.  QT prolongation with antimicrobial agents: understanding the significance.

Authors:  Robert C Owens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Drug-induced QT interval prolongation: mechanisms and clinical management.

Authors:  Senthil Nachimuthu; Manish D Assar; Jeffrey M Schussler
Journal:  Ther Adv Drug Saf       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.